New antibody drugs aim to stop Catheter-Related clots
NCT ID NCT06299111
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested two experimental drugs, REGN9933 and REGN7508, to see if they can prevent venous thromboembolism (blood clots) in adults who need a PICC line for at least 14 days. The drugs are monoclonal antibodies that target a clotting factor. 195 participants received a single IV dose of one of the drugs or a placebo. Researchers measured how many people developed clots, as well as side effects and bleeding risks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
REGN9933 and REGN7508 (monoclonal antibodies against factor XI)
What this could lead to
If successful, these drugs could offer a new way to prevent dangerous blood clots in people with central catheters, potentially reducing the need for standard blood thinners.
What could go wrong
This is an early Phase 2 trial with only 195 participants, so results may not apply to everyone. The drugs could cause bleeding or other side effects, and they may not work better than placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VENOUS THROMBOEMBOLISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arensia Exploratory Medicine Clinic at Country Hospital Cluj-Napoca
Cluj-Napoca, 400006, Romania
-
Arensia Research Clinic
Bucharest, 011658, Romania
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Cardiff and Vale University Health Board - University Hospital Wales
Cardiff, Wales, CF14 4XW, United Kingdom
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
-
Hadassah University Medical Center
Jerusalem, 91120, Israel
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Juravinski Hospital
Hamilton, Ontario, L8V 1C3, Canada
-
Lakeridge Health
Oshawa, Ontario, L1G 2B9, Canada
-
Lanadio Medical Center
Netanya, 4244916, Israel
-
London Health Sciences Centre
London, Ontario, N6A 4L6, Canada
-
Memorial Sloan Kettering
New York, New York, 10065, United States
-
Mount Sinai Medical Center
New York, New York, 10029, United States
-
Rabin Medical Center
Petah Tikva, 49100, Israel
-
Shaare Zedek Medical Center
Jerusalem, Jerusalem, 9103102, Israel
-
Sheba Medical Center
Ramat Gan, 5265601, Israel
-
Soroka University Medical Center
Beersheba, Southern District, 84101, Israel
-
Sveta Sofia Hospital
Sofia, 1000, Bulgaria
-
Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
-
Tel Aviv Sourasky Medical Center
Tel Aviv, 64239, Israel
-
The Newcastle Upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, NE1 4LP, United Kingdom
-
University Health Network
Toronto, Ontario, M5G 2M9, Canada
-
University hospital Southampton
Southampton, Hampshire, SO16 6YD, United Kingdom